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Abstract
Background: Patients with ankylosing spondylitis (AS) are at increased risk of depression. This increased risk has
been hypothesized to be solely secondary due to AS-related symptoms, or additionally due to a common
inflammatory pathway. From a clinical perspective, it is important to know whether treatment with tumor necrosis
factor alpha inhibitors reduces depressive symptoms, while from a pathophysiological point of view, it would be
insightful to understand whether such an effect would be a direct result of reduced inflammation, the result of
reduced AS-related symptoms, or both. The objective of this study was to evaluate the effect of infliximab on
depressive symptoms in patients with AS in a randomized-controlled trial setting.
Methods: Data were retrieved from a subgroup of patients from the AS Study for the Evaluation of Recombinant
Infliximab Therapy (ASSERT). Patients were randomly allocated to infliximab (n = 16) or placebo (n = 7) until week 24,
after which all received infliximab until week 54. Associations between treatment group and depressive symptoms,
measured with the Center for Epidemiological Studies Depression scale (CES-D, range 0–60 (best-worst)) at baseline
and over time, were explored with generalized estimating equations (GEE).
Results: Mean CES-D score at baseline was 15.5 (SD 9.3) in the infliximab group and 17.3 (SD 5.7) in the placebo
group. Twelve patients (52%) had a CES-D score > 16, suggestive for clinical depression. After 24 weeks, mean CES-
D had decreased to 9.5 (SD 11.4) in the infliximab group, but was 18.0 (SD 6.9) in the placebo group. GEE revealed
larger improvements in depressive symptoms (B = − 6.63, 95%CI − 13.35 to 0.09) and odds of possible depression
(OR = 0.02, 95%CI 0.00 to 0.72) in the infliximab group, compared to the placebo group. Both associations largely
disappeared when adjusted for self-reported disease activity and/or physical function. Additional adjustment for C-
reactive protein (CRP) did not change results.
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Conclusions: Depressive symptoms are common in patients with AS and active disease. Infliximab improves these
depressive symptoms in AS when compared to placebo by improving disease symptoms. We did not find an
indication for a direct link between CRP-mediated inflammation and depressive symptoms.
Trial registration: Trial registration (ASSERT): NCT00207701. Registered on September 21, 2005 (retrospectively
registered).
Keywords: Ankylosing spondylitis, Depressive symptoms, Anti-TNF-α therapy, Randomized controlled trial
Background
Ankylosing spondylitis (AS) affects not only the patients’
physical health, but also their mental well-being. A sys-
tematic review showed that patients with AS have an in-
creased prevalence of depressive symptoms, with rates
ranging between 11 and 64% [1]. Comorbid depression
in AS impacts the individual and has societal relevance,
as it has been associated with work disability in inflam-
matory arthritis [2].
Different possible pathways might explain the increased
prevalence of depressive symptoms in AS. Depressive symp-
toms could be secondary to disease-related impairments
such as pain and limitations in physical functioning, or to
psychological consequences such as worrying about the fu-
ture [3]. But AS and depressive symptoms may also share a
common pathophysiological pathway as both may be the re-
sult of an auto-inflammatory biological process; pro-
inflammatory biomarkers, such as C-reactive protein (CRP)
and tumor necrosis factor (TNF)-α, have been found to be
higher in depressed individuals compared to non-depressed
individuals, leading to the “inflammatory/cytokine hypoth-
esis of depression” [4]. Also, a randomized controlled trial
revealed that TNF-α inhibitors (TNFi) can improve depres-
sive symptoms in patients with treatment-resistant depres-
sion and increased inflammatory markers [5].
From a clinical perspective, it is of importance to
understand whether treatment with TNFi can reduce de-
pressive symptoms in patients with AS. From a patho-
physiological point of view, it might be interesting to
understand if such an effect would be the result of a re-
duction of AS-related symptoms, inflammation, or both.
Previously, several studies have reported improvements
in depressive symptoms in patients with AS after treat-
ment with infliximab [6–8]. Interestingly, observations
on the mechanism behind this (potential) effect of inflix-
imab were not equivocal, as correlations of depressive
symptoms with either AS-related symptoms (self-re-
ported disease activity) [8] or inflammatory biomarkers
[6] have been reported. None of these studies was
placebo-controlled or blinded, however, and the ob-
served improvements could have been the result of re-
gression to the mean. In two randomized controlled
trials (RCTs), etanercept improved depressive symptoms
in patients with AS and non-radiographic axial
spondyloarthritis (nr-axSpA), although reported effects
were small, and the nature of the effect of TNFi on de-
pressive symptoms was not further explored [9, 10].
The objectives of the present study were to evaluate in
patients with AS the effect of infliximab on depressive
symptoms compared to placebo and to explore the asso-
ciation between depressive symptoms and AS-related
symptoms (experienced disease activity and physical
functioning) and inflammation over time.
Patients and methods
Data were retrieved from a sub-study of the Ankylosing
Spondylitis Study for the Evaluation of Recombinant
Infliximab Therapy (ASSERT), which originally random-
ized 279 patients. Patients from ASSERT that had been
included in the Maastricht University Medical Centre
were considered eligible for the current sub-study, and
asked to complete a questionnaire on depressive symp-
toms in parallel to the protocol-required assessments of
ASSERT. The ancillary study population consisted of 23
patients, 16 patients randomly assigned to infliximab
and 7 to placebo.
Study design
The design of the ASSERT RCT has been previously re-
ported [11]. Briefly, patients were included in ASSERT if
they were 18 years or older and classified as AS accord-
ing to the modified New York criteria. Patients had to
have a Bath AS Disease activity index (BASDAI) score > 4
and a spinal pain assessment score > 4 on a visual analog
scale [12]. Patients were randomly assigned (3:8 ratio) to
receive infusions of 5 mg/kg infliximab or placebo at
weeks 0, 2, 6, 12, and 18. From week 24 until week 54,
all patients received infliximab therapy. The study proto-
col was reviewed and approved by the independent eth-
ics committee (METC azM/UM). All patients provided
written informed consent.
Study outcomes
Depressive symptoms were assessed with the Center
for Epidemiologic Studies Depression scale (CES-D)
[13, 14]. This validated instrument was chosen since
it contains fewer somatic items than other instru-
ments [15]. The CES-D consists of 20 items on
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perceived mood and level of functioning during the
past week. Every item is scored on a 4-point scale,
where 0 = rarely or none of the time, 1 = some or lit-
tle of the time, 2 = occasionally or a moderate amount
of time, and 3 = most of the time. The total CES-D
score is the sum of all items (range 0 [best] to 60
[worst]). In addition, four CES-D subscales have been
defined (“Somatic-retarded activity” [range 0–21],
“Depressed affect” [range 0–15], “Positive affect”
[range 0–12] and “Interpersonal affect” [range 0–6]),
reflecting combinations of varying individual items
[16]. A total CES-D score of > 16 is employed as a
cutoff suggestive for clinical depression (i.e., “possible
depression”) and would warrant a referral for a diag-
nostic evaluation [14]. Self-reported disease activity
and physical function were measured with the BAS-
DAI and Bath AS Functional Index (BASFI), respect-
ively [17]. Inflammation was assessed with the serum
CRP. Study outcomes were assessed at weeks 0, 6, 12,
24, and 54. Both patients and assessors were blinded
until week 24. The main interest of the study was the
(between-group difference in) change from baseline
CES-D at week 24, in line with ASSERT, in which
the main outcome was assessed at the same point in
follow-up.
Statistical analysis
Differences in baseline characteristics between groups were
explored with independent t test, Mann Whitney test, or
chi-square test, depending on level of measurement and
distribution. Fisher’s exact test was preferred over chi-
square test for small samples (expected count < 5). Chi-
square tests (or Fisher’s exact tests) and Mann-Whitney U
tests were used to respectively compare the proportion of
patients with a CES-D score > 16 and the mean CES-D
scores between groups at the different time points.
The course of CES-D scores between groups over time
(until week 24, as thereafter both groups were on inflixi-
mab) was compared using generalized estimating equa-
tion (GEE) analyses. GEE can take into account the
within-subject correlation in a longitudinal study, i.e. the
dependency that exists between assessments within the
same subject [18, 19]. GEE is focused on estimating the
average outcome in the population (population-averaged
model), and the model estimates reflect both within-
subject and between-subject effects. It requires an a
priori defined “working correlation structure”. For this
analysis, an “exchangeable” correlation structure was
chosen, based on the similar correlations of CES-D
scores between time points [19].
First, separate GEE analyses were carried out with either
continuous CES-D scores, or dichotomized CES-D score
(normal [< 16] vs. increased [≥ 16]), as the outcome
(dependent variable). Considering the small sample size,
only a limited number of variables could be included in
the GEE. Group (infliximab versus placebo) and time (cat-
egorical) were included as independent variables, as was
as an interaction between group and time (group*time), to
test whether there was a difference in the outcome
(change from baseline CES-D [continuous] or change
from baseline odds of increased CES-D [dichotomized])
between the groups after the first 24 weeks. The GEE ana-
lyses were adjusted for baseline CES-D. Second, as we
were specifically interested in the mechanism behind (im-
provement of) depressive symptoms in AS, we explored
whether a potential association between infliximab and re-
duced depressive symptoms remained after adjustment for
time-varying AS-specific variables of disease symptoms
(BASDAI or BASFI; added as independent variables to the
initial model with group, time, group*time and baseline
CES-D as independent variables), as well as inflammation
(CRP; added as independent variable to the initial model
with group, time, group*time and baseline CES-D as inde-
pendent variables), or both. Of note, BASDAI and BASFI
were added in separate models due to collinearity. In
ASSERT, treatment allocation was stratified by CRP
(within or above 3 times the upper limit of normal); for
the current sub-study, we did not adjust for this stratifica-
tion, as CRP was one of our variables of interest and in
light of the sample size. For all analyses, p < 0.05 was con-
sidered statistically significant. Analyses were performed
with R, version 3.5.3 [20].
Results
At baseline, the groups were largely comparable in terms
of demographics and disease characteristics, although
the placebo group contained only male patients and had
slightly (though statistically non-significant) higher mean
BASFI and Patient Global (Table 1). At weeks 6, 12, 24
and 54, a CES-D score was missing for 1, 2, 0 and 2 pa-
tients, respectively; none of the patients had more than 1
missing CES-D score. The mean CES-D score at baseline
was 15.5 (SD 9.3) in the infliximab group and 17.3 (SD
5.7) in the placebo group. Fifty-six percent (9 of 16) of
the patients in the infliximab group and 43% (3 of 7) in
the placebo-group had a CES-D score > 16 at baseline,
suggestive for clinical depression. The scores on the four
CES-D subscales did not differ between groups at base-
line (see Additional file 1). When comparing the current
sub-study population (n = 23) to those who did partici-
pate in ASSERT but not part of this sub-study (n = 256),
the ancillary study patients had slightly higher scores on
BASDAI (7.0 [SD 1.1] versus 6.4 [SD 1.6]) and BASFI
(6.6 [SD 1.5] versus 5.7 [SD2.0]) (see Additional file 2).
Course of CES-D over time
In the first 24 weeks after baseline, CES-D in the inflixi-
mab group decreased substantially compared to the
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placebo group (Fig. 1a). Within groups, the mean (SD)
[change from baseline (Δ), number of patients who com-
pleted the CES-D at that time point] CES-D score at
week 6 had decreased to 10.3 (SD 7.7) [Δ − 5.2, n = 16]
in the infliximab group and 15.9 (SD 6.0) [Δ − 2.5, n = 6]
in the placebo-group (p = 0.03 for comparison of abso-
lute CES-D). At 24 weeks, mean CES-D scores were 9.5
(SD 11.4) [Δ − 6.0, n = 16] in the infliximab group and
18.0 (SD 6.9) [Δ + 0.6, n = 7] in the placebo group (p =
0.02 for comparison of absolute CES-D). At week 54, 30
weeks after the original placebo group had switched to
infliximab, the mean CES-D score in the original placebo
group had decreased to the same degree as the inflixi-
mab group (9.5 (SD 13.1) [Δ − 9.3, n = 5] vs. 8.6 (SD 8.4)
[Δ − 6.9, n = 16], p = 0.90 for comparison of absolute
CES-D). Similar changes over time were observed in
both groups for BASDAI (Fig. 1b).
Exploration of the CES-D subscales showed scores in
the infliximab group had improved strongest in the first
24 weeks after baseline for the subscale “Somatic-re-
tarded activity” and to a lesser extent for the subscale
“Depressed affect”, when compared to the placebo group
(see Additional file 1).
At week 6, 25% (4 of 16) of the infliximab group had a
CES-D score > 16 suggestive for clinical depression,
compared to 50% (3 of 6) in the placebo group (p = 0.33)
(Fig. 2). After 24 weeks, these proportions were 13% (2
of 16) and 71% (5 of 7), respectively (p = 0.01). At week
54, when all patients received infliximab, 20–25% (1 of 5
of the original placebo group, 4 of 16 of the original
infliximab group) had a CES-D score > 16.
GEE analysis of factors associated with CES-D over time
Differences in disease course between treatment groups
over time were explored by GEE. As expected, BASDAI
scores in the first 24 weeks were significantly lower in
the infliximab group compared to the placebo group
(Bgroup*time(24) = − 2.97, 95%CI − 4.51 to − 1.42, p < 0.01).
This effect was partially explained by a reduction in in-
flammation (reflected by CRP) in the infliximab group,
as observed in separate models in which CRP was in-
cluded in addition to treatment (data not shown).
Further exploration of depressive symptoms by GEE
revealed a (borderline non-significant) larger improve-
ment in CES-D scores in the infliximab group compared
to the placebo group after the first 24 weeks (model 1A:
Bgroup*time(24) = − 6.63, 95%CI − 13.35 to 0.09, p = 0.05).
After adjustment for BASDAI, no association was ob-
served anymore between infliximab and change in CES-
D scores over time (model 1B: Bgroup*time(24) = − 2.66,
95%CI − 9.44 to 4.11, p = 0.44), while BASDAI itself was
significantly associated with CES-D scores (model 1B:
Table 1 Baseline characteristics separately for patients in the infliximab and placebo arm
Infliximab (n = 16) Placebo (n = 7) p
Male gender, n (%) 11 (68.8) 7 (100.0) 0.27
Age, years 38.6 (11.6) 44.9 (5.8) 0.19
Disease duration, years 8.3 (8.2) 11.5 (7.4) 0.37
HLA-B27 positive, n (%) 14 (87.5) 5 (71.4) 0.56
History of uveitis, n (%) 6 (37.5) 1 (14.3) 0.37
History of psoriasis, n (%) 0 (0.0) 0 (0.0) –
History of IBD, n (%) 2 (12.5) 1 (14.3) 1.00
BASDAI score, 0–10 7.0 (1.3) 7.1 (0.7) 0.55
BASFI score, 0–10 6.3 (1.5) 7.2 (1.3) 0.21
Patient’s global assessment, 0–10 VAS 6.8 (1.4) 7.8 (1.2) 0.15
Mander enthesis index, 0–90 7.7 (8.6) 12.8 (14.6) 0.69
Swollen joint index, 0–44 2.9 (3.7) 3.0 (3.9) 0.86
Chest expansion, cm 2.0 (0.9) 2.5 (2.0) 0.87
Night pain, 0–10 VAS 6.4 (2.0) 7.4 (1.0) 0.11
CRP level, mg/L 26.0 (24.4) 15.4 (16.0) 0.22
Increased CRP, n (%)* 13 (81.3) 6 (85.7) 1.00
CES-D score, 0–60 15.5 (9.3) 17.3 (5.7) 0.66
Increased CES-D, n (%)† 9 (56.3) 3 (42.9) 0.67
Values expressed as mean (SD), unless otherwise indicated
HLA-B27 human leucocyte antigen-B27, IBD inflammatory bowel disease, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing
Spondylitis Functional Index, VAS visual analog scale, CRP C-reactive protein, CES-D Center for Epidemiologic Studies Depression Scale
*Defined as CRP > 5mg/L
†Defined as a score ≥ 16, indicating possible depression
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BBASDAI = 1.34, 95%CI 0.53 to 2.15, p < 0.01) (Table 2).
Adjustment for CRP instead of BASDAI had a notably
smaller effect on the association between infliximab
treatment and CES-D scores (model 1C: Bgroup*time(24) =
− 5.71, 95%CI − 12.53 to 1.12, p = 0.10). Finally, when
both BASDAI and CRP were included, BASDAI
remained associated with CES-D scores, while CRP was
not (model 1D, Table 2).
When exploring the odds of possible depression (CES-
D score ≥ 16) as the outcome, while adjusting for base-
line CES-D status (increased (> 16) vs normal (< 16)),
findings were similar: infliximab treatment was associ-
ated with a larger reduction in odds of having an in-
creased CES-D after 24 weeks (model 2A:
ORgroup*time(24) = 0.02, 95%CI 0.00 to 0.72, p = 0.03), but
after adjustment for BASDAI, this association was no
longer significant (model 2B: ORgroup = 0.03, 95%CI 0.00
to 1.32, p = 0.07) (Table 2). After adjustment for CRP in-
stead of BASDAI, a similar observation was made
(model 2C: ORgroup*time(24) = 0.03, 95%CI 0.00 to 1.30,
p = 0.07) (Table 2). Adjustment for both BASDAI and
CRP resulted in none of these (treatment or BASDAI or
CRP) being significantly associated with increased CES-
D scores (model 2D, Table 2).
Analyses using BASFI instead of BASDAI led to simi-
lar results: after adjustment for BASFI, the initial associ-
ation between treatment group and CES-D scores was
no longer observed, and when both BASFI and CRP
were included, BASFI was associated with CES-D, while
CRP was not (models 3A–3D, Table 3). Using the odds
of possible depression (CES-D score ≥ 16) as outcome
yielded similar results, although BASFI remained
Fig. 1 CES-D (a) and BASDAI (b) scores over time according to treatment group. Figure caption: Course of mean CES-D (a) and BASDAI (b) scores
over time, by treatment group. During the open-label extension, all patients received infliximab. BASDAI, Bath Ankylosing Spondylitis Disease
Activity Index; CES-D, Center for Epidemiologic Studies Depression Scale; SE, standard error
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associated with possible depression, also after adjust-
ment for CRP (models 4A–4D, Table 3).
Discussion
This study showed that depressive symptoms are com-
mon in patients with AS that have high disease activity.
Infliximab improved depressive symptoms in patients
with AS after 24 weeks of treatment. This effect could
largely be explained by the effect of infliximab on self-
reported symptoms of AS.
Over half of the patients with AS and active disease had
a CES-D score > 16 at baseline, indicative for possible de-
pression. This high proportion seems to be on the upper
end of the prevalence range as reported in the literature,
but is likely the result of the inclusion criteria for ASSE
RT, which required patients to have active disease [1]. For
comparison, in control populations in the Netherlands, a
possible depression as measured by increased CES-D
score has been reported in 5–22% [21–23].
The reduction in depressive symptoms in the inflixi-
mab group occurred already within the first weeks and
was maintained during the remainder of follow-up. Im-
portantly, treatment with infliximab was not only associ-
ated with a decrease in depressive symptoms, but also
with decreased odds of CES-D scores above the thresh-
old for (probable) depression. The substantial reduction
(an estimated 98% reduction in odds of having an in-
creased CES-D after 24 weeks of weeks of infliximab
compared to placebo), although certainly an overesti-
mation of the effect of infliximab on true clinical depres-
sion, seems clinically relevant. This implicates that, at
least in a population of patients with active AS, inflixi-
mab not only decreases the severity of depressive symp-
toms and odds of probable depression, but potentially
even lowers the odds of true clinical depression. Of note,
even after up to 54 weeks of treatment, 20–25% of both
groups still had CES-D scores suggestive of possible
depression.
Comparing our results with other studies that investi-
gated the effect of TNFi on depressive symptoms in AS
is difficult, because other study designs and/or instru-
ments were used to assess depressive symptoms (in none
the CES-D was used) [6–10]. Two RCTs assessed the ef-
fect of etanercept on depressive symptoms as a second-
ary outcome or in post hoc analysis. The first study,
comparing sulfasalazine to etanercept among 566 pa-
tients with AS, reported significant improvements in de-
pressive symptoms after 16 weeks in both treatment
arms, with larger improvements in the etanercept group
[9]. In the second study, where 215 patients with nr-
axSpA were treated with etanercept or placebo for 12
weeks followed by etanercept for all subjects for another
12 weeks, depressive symptoms did not differ between
groups after 12 weeks or 24 weeks, but had improved
from baseline after 24 weeks in both groups [10]. In
addition, three observational studies on the effect of
infliximab on depressive symptoms in AS were pub-
lished, with a total of 52 patients and all of limited dur-
ation (6–12 weeks) [6–8]. In line with our findings, in
these observational studies, similar proportions of pa-
tients with depression scores above the threshold for the
respective depression instrument used at baseline and
over time were observed [7, 8]. Also, improvements in
depressive symptoms occurred already within the first
weeks after initiation of infliximab. Of note, none of
these studies explored whether these improvements can
be fully explained by improvements in symptoms or
inflammation.
It remains challenging whether our results can help to
understand if AS has a direct (inflammatory) or indirect
(through pain and limitations) effect on depressive
symptoms. The association between treatment with
infliximab and improvement of depressive symptoms
largely disappeared after adjustment for AS-specific
symptoms, i.e. self-reported disease activity and physical
function, suggesting the change in depressive symptoms
in these patients is (at least partially) secondary to
changes in their AS-related symptoms. Of note, the rela-
tionship between self-reported depressive symptoms and
self-reported AS-related symptoms could (partially) be
bidirectional. In rheumatoid arthritis, for example, the
patient visual analog scale component of the Disease Ac-
tivity Score (DAS28) has been strongly associated with
depression [24]. Likewise, in the current study, responses
on BASDAI or BASFI could be influenced by the pa-
tient’s emotional state. Additionally, it is known some
covariance exists between all self-reported measures,
which likely adds to some overestimation of the ob-
served associations. Notwithstanding, when considering
an alternative explanation for the improvements in
Fig. 2 Proportion of patients with CES-D score≥ 16 over time
according to treatment group. Figure caption: Proportion of patients
with an increased CES-D score (≥ 16) at each assessment, by
treatment group. *From week 24 onwards, all patients received
infliximab. CES-D, Center for Epidemiologic Studies Depression Scale
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depressive symptoms, i.e. a reduction in inflammation,
CRP did not seem to independently/directly contribute
to the effect of infliximab treatment on depressive symp-
toms: adjustment for CRP did have a minor impact on
the association between infliximab and depressive
symptoms when compared to the effect of BASDAI
or BASFI, suggesting little mediation of the effect of
infliximab via CRP-mediated inflammation. This fur-
ther suggests the mechanism behind depressive symp-
toms in these patients is mainly based on the impact
of AS-related symptoms. It should be noted, however,
that due to the small sample size, these secondary
analyses were only exploratory and no elaborate path
analyses could be conducted. Nonetheless, the associ-
ation between CRP and depressive symptoms, com-
pared with BASDAI or BASFI, was not only
statistically non-significant but also very small numer-
ically, suggesting a direct effect of CRP-mediated in-
flammation would be little (if any) in a larger sample.
Overall, it remains challenging to unravel the intricate
relationships between the inflammatory pathophysio-
logical process behind AS, AS-related symptoms, and
depression. While CRP is commonly used as inflam-
matory biomarker in axSpA, we cannot rule out CRP
is not appropriate as a biomarker to identify a poten-
tial link between inflammation and depression in this
disease. While the current results do not allow us to
draw firm conclusions regarding these associations
between markers of inflammation and depression, our
data suggests other inflammatory biomarkers are
likely more interesting to further explore than CRP.
In addition, two other interesting observations can be
made. First, while all patients had high BASDAI and
BASFI scores at baseline, only half of these patients had
CES-D scores above the threshold for possible depres-
sion, indicating the relation between experienced pain or
functional limitations and depression is not an absolute
one. Second, baseline CES-D remained strongly associ-
ated with the course of CES-D over time, even when ac-
counting for BASDAI or BASFI. This suggests that,
while the effect of infliximab on depressive symptoms
seems to be mostly mediated by improvement in pain
and functional limitations, depressive symptoms as mea-
sured with the CES-D are additional and distinct phe-
nomena rather than only a reflection of these pain and
limitations. It would be interesting to further explore
which patients with active disease have an increased sus-
ceptibility to depression, for example as a result of gen-
etic predisposition or personality and coping traits [25].
On this line, it has recently been shown that illness per-
ceptions have an important role in the relationship be-
tween back pain and mental health outcomes [26].
Further, in axSpA, patients with comorbid depression
are much more likely to suffer from other mental health
and substance abuse disorders, also suggesting an under-
lying vulnerability [27].
The main limitation of this study is the small
number of patients restricting the power to detect
significant changes and limiting the number of cov-
ariables that could be included in the models. How-
ever, strong and clinically relevant absolute changes
and improvements in depressive symptoms were ob-
served. Further, we should realize that the CES-D is
a screening questionnaire which cannot be used to
diagnose depression, for which the gold standard still
is psychiatric interviewing and examination. On this
line it should be noted the questions in the CES-D
refer to the past week, which might further reflect
reactive depressive symptoms (instead of clinical de-
pression/chronic depression), overestimating the pro-
portion with actual depression. The associations as
observed in the analyses of the current study are
possibly an overestimation (numerically), and the ef-
fect of infliximab on true (physician-diagnosed) clin-
ical depression might be smaller in daily practice.
Finally, we did not have data available on the indi-
vidual BASDAI items, precluding analysis of the con-
tribution of each item.
The findings in the present study have several implica-
tions. Rheumatologists should be aware of the high
prevalence of depressive symptoms in patients with AS
and active disease, while considering that these symp-
toms are not strictly a result of pain and loss of func-
tioning. In addition, our results suggest that treatment
with a TNFi is beneficial for depressive symptoms in the
majority of this population. Still, a proportion of patients
seem to maintain clinically significant depressive symp-
toms despite TNFi treatment, which might require spe-
cialized treatment.
Conclusions
The prevalence of depressive symptoms was high among
this patient population with active AS. TNFi treatment
improved the depressive symptoms of AS patients; our
data suggest that this benefit seems an indirect effect of
TNFi treatment on AS-related symptoms. Appropriate
management of depression in AS deserves attention in
clinical practice.
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